The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy and safety of second-line regorafenib after sorafenib or lenvatinib first line in patients with unresectable hepatocellular carcinoma: A real-world study.
 
Feng Xue
No Relationships to Disclose
 
Jian Zhai
No Relationships to Disclose
 
Jianwei Liu
No Relationships to Disclose
 
Zhigang Fu
No Relationships to Disclose
 
Yanfu Sun
No Relationships to Disclose
 
Ruiliang Ge
No Relationships to Disclose
 
Shilei Bai
No Relationships to Disclose
 
Xiaowei Li
No Relationships to Disclose
 
Kui Wang
No Relationships to Disclose
 
Zengqiang Qu
No Relationships to Disclose